10-20

Title Average Ratingsort ascending
Fibromyalgia Symptoms Are Reduced by Low-Dose Naltrexone: A Pilot Study. 95.00%
A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone mela 90.00%
Does chemosensitivity-assay-directed therapy have an influence on the prognosis of patients with malignant melanoma stage IV? .. 90.00%
Low-dose naltrexone therapy improves active Crohn's disease. 90.00%
Dendritic cell-based vaccination in combination with gemcitabine/S-1 in patients with advanced pancreatic cancer. Sub-category: 90.00%
Pomegranate juice does not impair clearance of oral or intravenous midazolam, a probe for cytochrome P450-3A activity........... 90.00%
Pilot Study of Sentinel-Node-Based Adoptive Immunotherapy in Advanced Colorectal Cancer. 90.00%
Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic soli 90.00%
A preliminary naturalistic study of low-dose ketamine for depression and suicide ideation in the emergency department. 90.00%
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. 80.00%
Dramatic prostate-specific antigen response with activated hemicellulose compound in metastatic castration-resistant prostate ca 80.00%
Metronomic antiangiogenetic biochemotherapy of non-small cell lung cancer patients .... 80.00%
Removed from Pubmed because of suspiion of scientific fraud: Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF. 75.00%
A phase I trial of surgical resection with biodegradable carmustine (BCNU) wafer placement followed by vaccination.............. 70.00%
Trastuzumab in combination with metronomic cyclophosphamide and methotrexate in patients with HER-2 positive metastatic bre 70.00%
Antitumor activity of patient-derived renal cell carcinoma cells fused with allogeneic dendritic cells: In vitro results and cli 70.00%
A Phase I/IIA, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Crossover, Dose-Escalation, Safety Study of the Chemot 70.00%
Phase II trial of pharmacodynamically (PDally)-guided optimal biologic dose titration (OBDT) of sorafenib (S) in combination wit 70.00%
Oral metronomic cyclophosphamide in elderly with metastatic melanoma. 70.00%
Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. 70.00%
A pilot study of individualized maximum repeatable dose (iMRD), a new dose finding system, of weekly gemcitabine for patients wi 60.00%
Synchronization of cortisol circadian rhythm by the pineal hormone melatonin in untreatable metastatic solid tumor patients and 60.00%
Alert because of Scientific Fraud: Immunotherapy of HIV-infected patients with Gc protein-derived macrophage activating factor (GcMAF). 55.00%
Results of Ukrain monotherapy of prostate cancer 50.00%
Immunologic effector mechanisms of a standardized mistletoe extract on the function of human monocytes and lymphocytes in vitro, 50.00%
Chemoradiotherapy with twice-weekly administration of low-dose gemcitabine for locally advanced pancreatic cancer. 50.00%
Long-term safety of BLP25 liposome vaccine (L-BLP25) in patients (pts) with stage IIIB/IV non-small cell lung cancer (NSCLC). 50.00%
Phase I adjuvant trial of multi-epitope p53 vaccine for patients with squamous cell carcinoma of the head and neck (SCCHN): A pr 45.00%
Phase I trial of capecitabine (Cap) and gemcitabine (G) with concurrent radical radiotherapy in locally advanced pancreatic ca.. 40.00%
Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab.... 40.00%
Correlation between prior therapeutic dendritic cell vaccination and the outcome of patients with metastatic melanoma treated... 30.00%